Combination of Venetoclax and hypomethylating agents in relapsed/refractory acute myeloid leukemia: A case series from a single center.

Q2 Medicine
Journal of Buon Pub Date : 2021-09-01
Sema Secilmis, Mehmet Sinan Dal, Merih Kizil Cakar, Alparslan Merdin, Nuran Ahu Baysal, Fevzi Altuntas
{"title":"Combination of Venetoclax and hypomethylating agents in relapsed/refractory acute myeloid leukemia: A case series from a single center.","authors":"Sema Secilmis,&nbsp;Mehmet Sinan Dal,&nbsp;Merih Kizil Cakar,&nbsp;Alparslan Merdin,&nbsp;Nuran Ahu Baysal,&nbsp;Fevzi Altuntas","doi":"","DOIUrl":null,"url":null,"abstract":"<p><strong>Purpose: </strong>Venetoclax (VEN) is an oral selective inhibitor of antiapoptotic protein B-cell leukemia/lymphoma-2 (BCL-2).</p><p><strong>Methods: </strong>We report 7 relapsed/refractory (R/R) acute myeloid leukemia (AML) patients treated with venetoclax and hypomethylating agents (HMA).</p><p><strong>Results: </strong>More than half of the patients could go on with venetoclax for only a few months.</p><p><strong>Conclusion: </strong>Using venetoclax combined with HMA in R/R AML should be kept in mind as an alternative salvage option.</p>","PeriodicalId":50248,"journal":{"name":"Journal of Buon","volume":" ","pages":"2026-2032"},"PeriodicalIF":0.0000,"publicationDate":"2021-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Buon","FirstCategoryId":"1085","ListUrlMain":"","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"Medicine","Score":null,"Total":0}
引用次数: 0

Abstract

Purpose: Venetoclax (VEN) is an oral selective inhibitor of antiapoptotic protein B-cell leukemia/lymphoma-2 (BCL-2).

Methods: We report 7 relapsed/refractory (R/R) acute myeloid leukemia (AML) patients treated with venetoclax and hypomethylating agents (HMA).

Results: More than half of the patients could go on with venetoclax for only a few months.

Conclusion: Using venetoclax combined with HMA in R/R AML should be kept in mind as an alternative salvage option.

Venetoclax联合低甲基化药物治疗复发/难治性急性髓性白血病:来自单一中心的病例系列
目的:Venetoclax (VEN)是一种抗凋亡蛋白b细胞白血病/淋巴瘤-2 (BCL-2)的口服选择性抑制剂。方法:我们报告了7例复发/难治性(R/R)急性髓性白血病(AML)患者使用venetoclax和低甲基化药物(HMA)治疗。结果:半数以上患者仅能坚持使用维妥乐几个月。结论:venetoclax联合HMA治疗R/R AML应作为一种替代的抢救选择。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
Journal of Buon
Journal of Buon 医学-肿瘤学
自引率
0.00%
发文量
0
审稿时长
4-8 weeks
期刊介绍: JBUON aims at the rapid diffusion of scientific knowledge in Oncology. Its character is multidisciplinary, therefore all aspects of oncologic activities are welcome including clinical research (medical oncology, radiation oncology, surgical oncology, nursing oncology, psycho-oncology, supportive care), as well as clinically-oriented basic and laboratory research, cancer epidemiology and social and ethical aspects of cancer. Experts of all these disciplines are included in the Editorial Board. With a rapidly increasing body of new discoveries in clinical therapeutics, the molecular mechanisms that contribute to carcinogenesis, advancements in accurate and early diagnosis etc, JBUON offers a free forum for clinicians and basic researchers to make known promptly their achievements around the world. With this aim JBUON accepts a broad spectrum of articles such as editorials, original articles, reviews, special articles, short communications, commentaries, letters to the editor and correspondence among authors and readers. JBUON keeps the characteristics of its former paper print edition and appears as a bimonthly e-published journal with continuous volume, issue and page numbers.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信